InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company offers Imipenem and Cilastatin sodium solution under the Bestnem brand for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents, such as gadopentetate dimeglumine under the Gadomni brand; oncology agents comprising bendamustine under the Innomustine brand; immunological agents under the Immurin brand; and Inpheno tablets for rare diseases. It also provides active pharmaceutical ingredient, including orphan drug and MRI enhancing agents. In addition, the company's product pipeline comprises D07001, which is in initiated phase II trial for treatment of pancreatic and lung cancer, as well as in phase III clinical trial to treat biliary tract cancer; D0191801, which is in preclinical trial to treat diabetes; D0221901, which is in preclinical trial to treat type II diabetes; D0282102 for the treatment of lymphocytic leukemia/multiple myeloma/non-hodgkin's lymphoma; O0242001-1, O0242001-2, O0242001-3 which is in preclinical trial to treat MRI agent. Further, it provides MUCR system, OralPas, and OralPas Pro technology platform. The company was founded in 1994 and is based in Taipei, Taiwan.